The product will be manufactured in China and the first batch must be delivered by July 9, but the folder tries to bring forward the deadline
After realizing the risk of shortages in the public network, the Ministry of Health informed this Monday, 15, that it has purchased 1.3 million units of insulin a fast-acting analogue (aspart molecule), enough to treat more than 67,000 patients nationwide who depend on this medicine. The contract with the Chinese company GlobalX was signed last Tuesday 9 and the first batch of the product should be delivered by 9 July.
The Ministry of Health is trying to bring forward the delivery of at least part of the lot. Rapid insulin is applied directly to the skin of the patient with diabetes, through an injector pen, and acts in less than 15 minutes, bringing blood sugar back to adequate levels. Therefore, it is vital to monitor the health of diabetics.
In a note released this Monday, the file reports that “the country is facing a scenario of lack of national production of rapid-acting analogue insulin in a sustainable way and able to meet needs”. In the last two open auctions for the purchase of this substance, no company has made any offers. For this reason, the Ministry has also allowed companies not registered with Anvisa to make proposals, provided they are registered with other health regulatory agencies that adhere to the International Council for Harmonization (ICH).
This is the case of insulin bought now (molecule of aspart, produced by the Gan & Lee company). The World Health Organization and Anvisa accept and recommend ICH registration for emergency situations.
To ensure that there is no insulin shortage in the Unified Health System (SUS) network until the product manufactured in China arrives, the ministry announced two more measures: the transfer of the stock between states and the authorization for the purchase by of the State Health Secretariats, with reimbursement by the Ministry of Health.
The expectation of the folder is that it will be possible to maintain an equal offer in the SUS network until the beginning of June. The ministry also informed that “the most commonly consumed regular insulins are in adequate stocks and the case of analogue rapid-acting insulin is treated with the highest priority with the suppliers”.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
